Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mibavademab in Generalized Lipodystrophy
NCT07220785Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- May 2028
- Countries
- 3
01
Overview
A Phase 3 trial of mibavademab in generalized lipodystrophy (GL), sponsored by Regeneron Pharmaceuticals. Started Mar 2026; status: recruiting.
02
Drugs
mibavademab
03
Conditions
generalized lipodystrophy (GL)
Beyond the preview
Go deeper on NCT07220785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07220785.